Other

Neurocrine Biosciences·Balance Sheet Statement·27 metrics

Breakdown

Loading...

Metrics

Operating Lease Income - 2023 (Lessor)

Operating Lease Income - 2024 (Lessor)

Current branded prescription drug fee

Income taxes payable – long-term

Accrued development costs

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Common stock, par value (in dollars per share)

Common stock, shares authorized (in shares)

Common stock, shares issued (in shares)

Common Stock, Shares, Outstanding

Debt Securities, Available-for-Sale, Unrealized Loss Position

Raw materials

Lessee Operating Lease Liability Payments Due

Thereafter

Lessee Operating Lease Liability Undiscounted Excess Amount

Lessor, Operating Lease, Payment to be Received, after Year Four

Remainder of fiscal 2026

Operating Lease Weighted Average Discount Rate Percent

Other noncurrent liabilities

Preferred Stock, Par or Stated Value Per Share

Preferred Stock, Shares Authorized

Preferred Stock, Shares Issued

Preferred Stock, Shares Outstanding

Prepaid development costs

Prepaid expenses

Provision for contract loss

Remainder of Fiscal Year 2024